Home > Publications database > MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome. > print

001     285997
005     20240229155118.0
024 7 _ |a 10.1016/j.jmoldx.2023.10.005
|2 doi
024 7 _ |a pmid:38061582
|2 pmid
024 7 _ |a 1525-1578
|2 ISSN
024 7 _ |a 1943-7811
|2 ISSN
024 7 _ |a altmetric:157412709
|2 altmetric
037 _ _ |a DKFZ-2023-02578
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Helderman, Noah C
|b 0
245 _ _ |a MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome.
260 _ _ |a Amsterdam [u.a.]
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1706514648_23419
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Feb;26(2):106-114
520 _ _ |a Screening for Lynch syndrome (LS) in colorectal cancer (CRC) and endometrial cancer (EC) patients generally involves immunohistochemical staining of the mismatch repair (MMR) proteins. In case of MLH1 protein loss, MLH1 promotor hypermethylation (MLH1-PM) testing is performed to indirectly distinguish constitutional MLH1 variants from somatic epimutations. However, in recent years a growing number of studies have reported that MLH1-PM and pathogenic constitutional MMR variants are not mutually exclusive. This study describes six new and 86 previously reported MLH1-PM CRCs or ECs in LS patients. Of these, methylation of the MLH1 gene promotor 'C region' was reported in 30 MLH1, six MSH2, six MSH6 and three PMS2 variant carriers at median ages at diagnosis of 48.5 (IQR 39-56.75), 39 (IQR 29-51), 58 (IQR 53.5-67) and 68 (IQR 65.6-68.5) years, respectively. For 31 MLH1-PM CRCs in LS patients from literature, only the 'B region' of the MLH1 gene promotor was tested, whereas for 13 literature cases the tested MLH1 gene promotor region was not specified. Collectively, these data indicate that a diagnosis of LS should not be excluded when MLH1-PM is detected. Clinicians should carefully consider whether or not follow-up genetic MMR gene testing should be offered, with age < 60-70 years and/or a positive family history amongst other factors being suggestive for a potential constitutional MMR gene defect.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Lynch syndrome
|2 Other
650 _ 7 |a MLH1 promotor hypermethylation
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a endometrial cancer
|2 Other
650 _ 7 |a genetic testing
|2 Other
650 _ 7 |a immunohistochemistry
|2 Other
650 _ 7 |a mismatch repair
|2 Other
650 _ 7 |a screening
|2 Other
700 1 _ |a Andini, Katarina D
|b 1
700 1 _ |a van Leerdam, Monique E
|b 2
700 1 _ |a van Hest, Liselotte P
|b 3
700 1 _ |a Hoekman, Daniël R
|b 4
700 1 _ |a Ahadova, Aysel
|0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000
|b 5
|u dkfz
700 1 _ |a Bajwa-Ten Broeke, Sanne W
|b 6
700 1 _ |a Bosse, Tjalling
|b 7
700 1 _ |a van der Logt, Elise M J
|b 8
700 1 _ |a Imhann, Floris
|b 9
700 1 _ |a Kloor, Matthias
|0 P:(DE-He78)028ee60cca729028708496826f077b58
|b 10
|u dkfz
700 1 _ |a Langers, Alexandra M J
|b 11
700 1 _ |a Smit, Vincent T H B M
|b 12
700 1 _ |a Terlouw, Diantha
|b 13
700 1 _ |a van Wezel, Tom
|b 14
700 1 _ |a Morreau, Hans
|b 15
700 1 _ |a Nielsen, Maartje
|b 16
773 _ _ |a 10.1016/j.jmoldx.2023.10.005
|g p. S1525157823002891
|0 PERI:(DE-600)2032654-3
|n 2
|p 106-114
|t The journal of molecular diagnostics
|v 26
|y 2024
|x 1525-1578
909 C O |p VDB
|o oai:inrepo02.dkfz.de:285997
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)028ee60cca729028708496826f077b58
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MOL DIAGN : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-24
920 1 _ |0 I:(DE-He78)F210-20160331
|k F210
|l KKE Angewandte Tumorbiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F210-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21